Cardiometabolic diseases

#Cardiometabolic diseases #NanoVation Therapeutics #Novo Nordisk #Partnership #Rare disease

Novo Nordisk and NanoVation enter multi-target partnership

Novo Nordisk and NanoVation Therapeutics have announced a multi-year partnership to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership will combine NanoVation Therapeutics’ long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and… Read More

#Business & Investment #News

Heart
#Cardiometabolic diseases #Novo Nordisk Foundation #Obesity

Novo Nordisk Foundation and cardiometabolic diseases 

Following a trip to Copenhagen, Denmark, DDW’s Megan Thomas reflects on the Novo Nordisk Foundation’s efforts to tackle cardiometabolic diseases.  According to presentations given at the Foundation’s HQ, more than 30% of the world’s population is overweight or obese and 537 million people live with diabetes. The World Health Organization… Read More

#Business & Investment #Exclusive Content #Opinion